DK1418942T3 - Poxvirus-holdige sammensætninger og fremgangsmåde til fremstilling deraf - Google Patents

Poxvirus-holdige sammensætninger og fremgangsmåde til fremstilling deraf

Info

Publication number
DK1418942T3
DK1418942T3 DK02796552T DK02796552T DK1418942T3 DK 1418942 T3 DK1418942 T3 DK 1418942T3 DK 02796552 T DK02796552 T DK 02796552T DK 02796552 T DK02796552 T DK 02796552T DK 1418942 T3 DK1418942 T3 DK 1418942T3
Authority
DK
Denmark
Prior art keywords
poxvirus
freeze
processes
preparation
containing compositions
Prior art date
Application number
DK02796552T
Other languages
English (en)
Inventor
Karl Heller
Paul Howley
Ingmar Raethe
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1418942(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of DK1418942T3 publication Critical patent/DK1418942T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
DK02796552T 2001-12-10 2002-11-28 Poxvirus-holdige sammensætninger og fremgangsmåde til fremstilling deraf DK1418942T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200101831 2001-12-10

Publications (1)

Publication Number Publication Date
DK1418942T3 true DK1418942T3 (da) 2005-11-28

Family

ID=8160885

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02796552T DK1418942T3 (da) 2001-12-10 2002-11-28 Poxvirus-holdige sammensætninger og fremgangsmåde til fremstilling deraf

Country Status (22)

Country Link
US (1) US7094412B2 (da)
EP (1) EP1418942B1 (da)
JP (1) JP4439263B2 (da)
KR (1) KR20040074067A (da)
CN (1) CN1296096C (da)
AT (1) ATE300954T1 (da)
AU (1) AU2002361962A1 (da)
BR (1) BR0214822A (da)
CA (1) CA2467365C (da)
DE (1) DE60205388T2 (da)
DK (1) DK1418942T3 (da)
EA (1) EA006880B1 (da)
ES (1) ES2247414T3 (da)
HK (1) HK1071295A1 (da)
HU (1) HUP0402179A3 (da)
IL (2) IL161590A0 (da)
MX (1) MXPA04005577A (da)
NO (1) NO20042958L (da)
NZ (1) NZ533302A (da)
PL (1) PL213326B1 (da)
UA (1) UA78738C2 (da)
WO (1) WO2003053463A2 (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
KR101044538B1 (ko) 2002-09-05 2011-06-27 버베리안 노딕 에이/에스 무혈청 조건하에서 일차세포의 배양 및 바이러스의 증식방법
CN1207005C (zh) 2002-10-31 2005-06-22 威世药业（如皋）有限公司 含生物活性物质的兔皮和其用途
WO2006029467A1 (en) * 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
JP5138601B2 (ja) * 2005-11-21 2013-02-06 サノフィ パストゥール リミテッド 組換えウイルス安定化製剤
JP2010526546A (ja) 2007-05-14 2010-08-05 バヴァリアン・ノルディック・アクティーゼルスカブ ワクシニアウイルス系及び組換えワクシニアウイルス系ワクチンの精製
US8617576B2 (en) * 2007-05-18 2013-12-31 Medimmune, Llc Preservation of bioactive materials by freeze dried foam
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
EA201270108A1 (ru) 2009-10-08 2012-08-30 Бавариан Нордик А/С Формирование полиспецифического t-клеточного ответа против вич у человека
BR112012029633A8 (pt) 2010-05-21 2017-12-05 Ah Usa 42 Llc Vetores do parapoxvírus contendo antígeno do vírus da raiva.
US10087423B2 (en) 2010-07-20 2018-10-02 Bavarian Nordic A/S Method for harvesting expression products
KR20130020963A (ko) 2010-07-20 2013-03-04 에이에이치 유에스에이 42 엘엘씨 파라폭스바이러스 벡터
EP2788021B1 (en) 2011-12-09 2017-01-18 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
KR20150058152A (ko) 2012-07-10 2015-05-28 트랜스진 에스아이 마이코박테리아 항원 백신
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
EP3092000A1 (en) 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
US10653766B2 (en) 2014-03-12 2020-05-19 Bavarian Nordic A/S Use of oil and water emulsions for increasing B cell responses with modified Vaccinia Ankara virus
PL3169341T3 (pl) 2014-07-16 2019-12-31 Transgene Sa Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej
DK3226894T3 (da) 2014-12-01 2019-10-21 Transgene Sa Stabile flydende vacciniavirus-formuleringer
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
KR20190097240A (ko) 2016-12-28 2019-08-20 트랜스진 에스.에이. 종양용해성 바이러스 및 치료 분자
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US11306292B2 (en) 2017-05-15 2022-04-19 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
MA49397A (fr) 2017-06-15 2020-04-22 Bavarian Nordic As Vecteurs à poxvirus codant pour des antigènes du vih, et leurs procédés d'utilisation
EP3641803A2 (en) 2017-06-21 2020-04-29 Transgene Personalized vaccine
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
MX2020009262A (es) 2018-03-07 2021-01-08 Transgene Vectores de parapoxvirus.
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
AU2019336940A1 (en) 2018-09-06 2021-03-11 Bavarian Nordic A/S Storage improved poxvirus compositions
WO2020090871A1 (ja) 2018-10-30 2020-05-07 国立大学法人東京大学 がん治療のための腫瘍溶解性ウイルス
AU2019412516A1 (en) 2018-12-28 2021-07-15 Transgene M2-defective poxvirus
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
WO2021180943A1 (en) 2020-03-12 2021-09-16 Bavarian Nordic A/S Compositions improving poxvirus stability
KR20230038496A (ko) 2020-07-13 2023-03-20 트랜스진 면역 억제의 치료
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2024003238A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S Epstein-barr-virus vaccine
WO2024003239A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (da)
US4380582A (en) * 1965-07-09 1983-04-19 The United States Of America As Represented By The Secretary Of The Army Preparation of dry variola virus
FR7773M (da) * 1968-06-14 1970-03-23
US3577526A (en) * 1969-06-13 1971-05-04 Merieux Inst Stabilized smallpox vaccine
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
JPH09504429A (ja) * 1993-10-12 1997-05-06 チロン ビアジーン，インコーポレイティド 組換えウイルスの保存方法
AU4556597A (en) * 1996-09-24 1998-04-17 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors

Also Published As

Publication number Publication date
DE60205388D1 (de) 2005-09-08
HUP0402179A2 (hu) 2005-01-28
UA78738C2 (en) 2007-04-25
CN1602205A (zh) 2005-03-30
BR0214822A (pt) 2004-12-14
ES2247414T3 (es) 2006-03-01
WO2003053463A2 (en) 2003-07-03
IL161590A0 (en) 2004-09-27
AU2002361962A1 (en) 2003-07-09
CN1296096C (zh) 2007-01-24
US20050019349A1 (en) 2005-01-27
NZ533302A (en) 2005-11-25
WO2003053463A3 (en) 2004-03-04
HUP0402179A3 (en) 2012-09-28
JP4439263B2 (ja) 2010-03-24
DE60205388T2 (de) 2006-03-30
EA006880B1 (ru) 2006-04-28
IL161590A (en) 2009-06-15
EP1418942A2 (en) 2004-05-19
ATE300954T1 (de) 2005-08-15
CA2467365C (en) 2012-11-20
PL213326B1 (pl) 2013-02-28
EA200400796A1 (ru) 2004-12-30
MXPA04005577A (es) 2005-04-19
EP1418942B1 (en) 2005-08-03
NO20042958L (no) 2004-07-09
KR20040074067A (ko) 2004-08-21
JP2005513109A (ja) 2005-05-12
CA2467365A1 (en) 2003-07-03
PL369954A1 (en) 2005-05-02
US7094412B2 (en) 2006-08-22
HK1071295A1 (en) 2005-07-15

Similar Documents

Publication Publication Date Title
DK1418942T3 (da) Poxvirus-holdige sammensætninger og fremgangsmåde til fremstilling deraf
MY129263A (en) Vaccine composition
GB0119011D0 (en) Treatment of nail infections
HK1060694A1 (en) Herbal compositions useful as chemopreventive and therapeutic agents.
EP1570840A3 (en) Topical composition comprising n-acetylaldosamines or n-acetylamino acids
BR0315767A (pt) Composição imunogência, método para fabricar uma vacina, kit, vacina, recipiente com uma superfìcie interna repelente à água, e, método para preservar uma composição que compreende ipv e um agente estabilizador
AR039688A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
WO2004060059A3 (en) Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
NO952863D0 (no) Fluoxetin-farmasöytiske sammensetninger
NO20030411L (no) Farmasöytiske sammensetninger for behandlingen av smertefulle, inflammatoriske og ulceröse tilstander av fuktige epiteloverflater slik sommukositt, stomatitt og Behcets syndrom
EP2275121A3 (en) Protein-based streptococcus pneumoniae vaccines
GT200100126A (es) Preparaciones de retardo de antibioticos de quinolona y procedimiento para su fabricacion.
WO2004080415A3 (en) Gel composition and method for treatment of vaginal infections
CN104606101A (zh) 一种辣木面膜
BR0208411A (pt) Composto, composição farmacêutica tópica e método para tratamento profilático ou terapêutico de doenças sexualmente transmitidas em um paciente humano, e, uso de um composto
NZ528544A (en) Formulations comprising entrapped active ingredients and uses thereof
WO2023150771A3 (en) Pharmaceutical composition for treatment and prevention of coronavirus infection
WO2003105672A3 (en) COMPOSITIONS AND METHODS OF CRYOSURGERY
ATE271876T1 (de) Verwendung einer synergistischen zusammensetzung zur herstellung eines medikaments zur behandlung von lebererkrankungen
MD2671F1 (en) Antiviral and antiherpetic medicine in the form of gel
PE20020218A1 (es) Uso de cepas de parapoxvirus ovis contra fibrosis de organos
TW200626127A (en) Dried material and method for producing the same
MD2789F1 (en) Entomologic antioxidant and immunomodulating preparation
BG2491U1 (bg) Хранителна добавка
WO2001051080A3 (en) Methods and compositions for obtaining disease protection for animals